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We have analyzed the possible relevance of HPV infection for breast cancer risk among Iranian women from north part of Iran.
Among women with breast cancer, 25.9% had positive test results for HPV DNA in breast tumor samples in contrast to 2.4% of
womenwithnoncancerstatus(P = 0.002).TheinfectionofHPVhasincreasedtheriskofbreastcancer(OR14.247;95%CI1.558–
130.284, P = 0.019). The high-risk HPV genotypes (types 16 and 18) in samples of breast cancer patients were the predominant
types (53.34%). Other genotypes detected in breast cancer were HPV-6, HPV-11, HPV-15, HPV-23, and HPV-124, and one isolate
could not be genotyped compared to HPV reference sequences. While the sole detected HPV in control specimens was HPV-124.
Our study reveals that HPV infection and age are the risk factors in breast cancer development in the north part of Iran.
1.Introduction
Breast cancer is the most common cancer in women world-
wide, and there were representing 22.9% of all new cancers
in 2008 (an estimated 1.378 million new cases) and ranking
second overall when both sexes are considered together [1].
Despite of good prognosis of breast cancer, it was also the
most common cause of death from cancer, with 13.7% of
deaths the world total in woman [1, 2]. Mazandaran pro-
vince is located in north of Iran and beneath the Caspian
Sea. According to the annual report of Health Deputy of
Ministry of Health and Medical Education in Iran, breast
cancer in women was representing 23.38% of all new cancers
in Mazandaran province in 2006-2007 and was the most fre-
quent cancer of women [3].
The incidence of breast cancer is increasing almost
everywhere, and this is due in part to increases in risk
factors including decreased childbearing and breast feed-
ing, increased exogenous hormone exposure, and harmful
dietary and lifestyle changes [2, 4]. On the other hand, breast
cancer development might be a consequence of diﬀerent
environmental exposures, including viral infection [4, 5].
Worldwide an estimated 12.1% of all human cancers (about
1.3 million cancer cases) were etiologically related to viral
agents in 2002 [5]. Hence, the correlation of viral agents with
breast cancer cannot be excluded.
There are controversial reports on the aetiology of HPV
in breast cancer around the world. In the last two decades,
considerable evidence has been found for a role for HPV
in human breast cancer [6–13] ,b u ts o m es t u d i e ss u g g e s t e d2 The Scientiﬁc World Journal
negative relationships [14–16]. In vitro studies have shown
that the main oncoproteins E6 and E7 from HPV16 are able
to immortalize primary mammary epithelial cells and pro-
vided additional evidence for a possible role of this virus in
breast carcinogenesis [17–19].
To our knowledge, this is the ﬁrst study on the presence
of HPVs and their relation with in breast cancer in Iranian
women. Our previous studies revealed that HPV infection
could be considered as a risk factor for the development of
lung cancer in Mazandaran population [20, 21]. In the pre-
sent study, we conducted a case-control study of breast can-
cer patients and controls and tried to ﬁnd a viral aetiology by
the detection of HPV genome, and to evaluate the possible
relevance of this factor for breast cancer risk among north
female Iranian population from Mazandaran province.
2.MaterialsandMethods
2.1. Tissue Samples. The study protocol was approved by
the scientiﬁc and ethics committee of the National Research
Institute of Tuberculosis and Lung disease, Tehran. A total of
130 blocks of paraﬃn-embedded tissue including 79 samples
diagnosedasbreastcarcinomas,and51noncancersamplesas
control were retrieved from archive of Imam Khomeini Hos-
pital, Medicine Faculty of Sari city, Mazandaran Universi-
ty of Medical Sciences, Iran between 2002 and 2009. It is
worth mentioning that the consents were acquired from the
patients during the healthcare and clinical services. Breast
ﬁbroadenomas served as control subjects in this study. Fur-
thermore to adjust the environmental confounders, we tried
to match the subject’s residence place in Mazandaran pro-
vince between both groups.
2.2. DNA Extraction and HPV DNA Detection. Genomic
DNAs from tissue sections were prepared according to the
methods that previously described [22]. To avoid contami-
nation of the DNA, great care was taken during extraction
and PCR (sectioning the blocks to several small groups at
diﬀerent times, using new surgical blade for each sample and
ﬁlter tips during extraction and PCR).
The adequacy of the DNA in each specimen for PCR am-
pliﬁcationwasdeterminedbythedetectionofa268-basepair
(bp) fragment of the β-globin gene using the GH20/PC04
primer set [23]. In case of negative results, the PC03/PC04
primer set was used to amplify the 110bp fragment. For the
detection of HPV genome, 3 diﬀerent primer sets including
the GP5+/GP6+ primers [24], the CP primers [25], and the
FAP primers [26] were applied in a way that described before
[10].
2.3. Sequencing and Phylogenetic Analysis. For genotyping of
HPV, the positive PCR products were analyzed by sequenc-
ing. The DNA sequence was determined with the Big-Dye
terminator cycle sequence kit and an ABI 377A sequencer
(Applied Biosystems Inc.).
The HPV partial sequences were edited with the BioEdit
software program version 7.0.5.2, and then phylogenetic
and molecular evolutionary analyses were conducted using
MEGAsoftwareversion4.0.2[27].TheUPGMAmethodwas
used for phylogenetic reconstructions that were implement-
ed in the MEGA 4.0.2 program. For the UPGMA method,
the nucleotide substitution model employed was the Max-
imum Composite Likelihood. Statistical conﬁdence for the
evolutionary trees was assessed by bootstrap (500 replicates).
The phylogenetic trees were drawn using the MEGA 4.0.2
program.
2.4. Nucleotide Sequence Accession Number. The nucleotide
sequences of HPV isolates that determined in this study have
been deposited in GenBank data base [accession numbers
HM748606–HM748622]. The GenBank accession numbers
for the reference HPV nucleotide sequences are as follows:
HPV-1 [V01116], HPV-2 [X55964], HPV-3 [X74462],
HPV-4[X70827],HPV-5[M17463],HPV-6[X00203],HPV-
7 [X74463], HPV-8 [M12737], HPV-9 [X74464], HPV-10
[X74465], HPV-11 [M14119], HPV-12 [X74466], HPV-13
[X62843], HPV-14 [X74467], HPV-15 [X74468], HPV-16
[K02718], HPV-17 [X74469], HPV-18 [X05015], HPV-19
[X74470], HPV-20 [U31778], HPV-21 [U31779], HPV-22
[U31780], HPV-23 [U31781], HPV-24 [U31782], HPV-25
[X74471], HPV-26 [X74472], HPV-27 [AB211993], HPV-28
[U31783], HPV-29 [U31784], HPV-30 [X74474], HPV-31
[J04353], HPV-32 [X74475], HPV-33 [M12732], HPV-34
[X74476], HPV-36 [U31785], HPV-37 [U31786], HPV-38
[U31787], HPV-39 [M62849], HPV-40 [X74478], HPV-41
[X56147], HPV-42 [M73236], HPV-43 [AJ620205], HPV-44
[U31788], HPV-45 [X74479], HPV-47 [M32305], HPV-48
[U31789], HPV-49 [X74480], HPV-50 [U31790], HPV-51
[M62877], HPV-52 [X74481], HPV-53 [X74482], HPV-54
[U37488], HPV-55 [U31791], HPV-56 [X74483], HPV-57
[X55965], HPV-58 [D90400], HPV-59 [X77858], HPV-60
[U31792], HPV-61 [U31793], HPV-62 [AY395706], HPV-63
[X70828], HPV-64 [U12495], HPV-65 [X70829], HPV-66
[U31794], HPV-67 [D21208], HPV-68 [X67161], HPV-69
[AB027020], HPV-70 [U21941], HPV-71 [AB040456], HPV-
72 [X94164], HPV-73 [X94165], HPV-74 [U40822], HPV-75
[Y15173], HPV-76 [Y15174], HPV-80 [Y15176], HPV-81
[AJ620209], HPV-82 [AB027021], HPV-83 [AF151983],
HPV-84 [AF293960], HPV-85 [AF131950], HPV-86
[AF349909], HPV-87 [AJ400628], HPV-88 [EF467176],
HPV-89 [AF436128], HPV-90 [AY057438], HPV-91
[AF419318], HPV-92 [AF531420], HPV-93 [AY382778],
HPV-94 [AJ620211], HPV-95 [AJ620210], HPV-96
[AY382779], HPV-97 [DQ080080], HPV-98 [NC 012744],
HPV-99 [NC 012745], HPV-100 [NC 012746], HPV-
101 [NC 008189], HPV-102 [DQ080083], HPV-
103 [NC 012750], HPV-104 [NC 012750], HPV-105
[NC 012747],HPV-106[DQ080082],HPV-107[EF422221],
HPV-108 [NC 012213], HPV-109 [NC 012485], HPV-110
[EU410348],HPV-111[EU410349],HPV-112[NC 012486],
HPV-113 [NC 012748], HPV-114 [NC 013931], HPV-
115 [NC 013591], HPV-116 [NC 013035], HPV-117
[GQ246950],HPV-119[GQ845441],HPV-120[GQ845442],
HPV-121 [NC 014185], HPV-122 [GQ845444], HPV-123
[GQ845445], HPV-124 [GQ845446], PcPV [X62844],
RhPV1 [M60184].The Scientiﬁc World Journal 3
B
4
-
G
P
B32-GP
81
B5-GP
B14-GP
75
96
HPV16
98
HPV51
HPV82
99
65
cHPV87
75
HPV84
HPV59
HPV114
HPV81
HPV57
HPV27b
98
HPV83
HPV72
HPV61
HPV62
HPV52
HPV40
HPV7
HPV91
HPV73
HPV34
HPV64
100 98 87 71 75
HPV32
HPV54
cHPV89
HPV67
B2-GP
B3-GP 98
HPV18
83
B1-GP
B12-GP
74
HPV10
HPV94
HPV117 94
87
HPV68
HPV43
B26-GP
HPV-11
B9-GP
B25-GP
90
HPV6b
79
RhPV1 PcPV1 HPV44 HPV55
89
HPV74 HPV13
HPV53
HPV30
99
HPV66
HPV56
HPV63
59
95
60
75
64
90
HPV45
HPV97
94
cHPV86
HPV39
HPV70
cHPV85
61
52
74
HPV26
HPV69
99
HPV42
HPV90
HPV106
65
HPV31
HPV29
HP
V3
HP
V28
5
5
57
HPV33
HPV58
69
77
HPV112
HPV119
98
HPV4
HPV65
85
HPV95
93
HPV60
HPV50
HPV88
75
HPV48
HPV116
HPV121
70
70
51
HPV115
HPV15
HPV110
HPV80
HPV76
HPV75
96
HPV96 HPV111 HPV122 HPV38 HPV22
HPV92 HPV104
66 HPV100
HPV23
HPV120 67
HPV9
HPV107
HPV17
HPV37 68
HPV103
HPV108
78
HPV101
91
HPV123
70
HPV109
96
HPV124
68
HPV20
84
HPV21
71
HPV14D
84
HPV19
HPV25
HPV49
HPV113
94
HPV24
61
HPV36
HPV5
68
HPV8
HPV12
HPV99
HPV47
HPV93
HPV98
84
63
56
73
83
53
55
HPV1a
HPV41
100
HPV2a
HPV71
HPV102
53
100
(a)
H
P
V
3
3
HPV58
98
HPV67
HPV52
HPV16
HPV31
56
HPV43
HPV91
68
HPV7
HPV40
99
93
HPV34
HPV73
100
HPV90
HPV106
100 HPV54
HPV6b
HPV-11
99
HPV44
HPV55
100
HPV74
HPV13
PcPV1
89
67
61 99 HPV32
HPV42
100 HPV94
HPV117
56
HPV10 78
HPV3
HPV28
67
66
HPV29 100
HPV18
HPV45
HPV97
100
HPV59
65
cHPV85
HPV68
HPV39
HPV70
57
77
83
81
HPV53
HPV30
100
HPV56
HPV66
92
100
HPV26 HPV69
99
HPV51 HPV82
100
84
HPV57 HPV27b
100
RhPV1
HPV61
HPV72
67
HPV81
HPV62
68
92
HPV83
cHPV89
HPV84
HPV114
54
cHPV86
cHPV87
76
99
98
100
H
P
V
1
1
2
H
P
V
1
1
9
100
H
P
V
6
0
H
P
V
8
8
H
P
V
4
HP
V65
HP
V95
5
1
100
HPV50
HPV48
53
54
HPV121
HPV109
HPV123
99
HPV116
HPV103
HPV108
98
HPV101
94
HPV5
HPV36
69
HPV47
HPV8
HPV12
HPV99
HPV19
HPV25
68
HPV20
HPV14D HPV21
57 83
96
54 HPV92 HPV96 HPV93
HPV98 85 HPV24 86 HPV124
C35-CP
B49-CP
100
100 HPV76
HPV75
99
HPV49
96
HPV115
HPV107
HPV104
86
HPV113
HPV122
HPV38
HPV111
HPV9
HPV22
B32-CP
B66-CP
98
HPV23
100
HPV120
98
HPV100
HPV110
HPV17
HPV37
54
HPV80
HPV15
B21-CP
100
90
72
77
99
98
84
HPV41
HPV1a
HPV63
54
99
100
HPV2a
HPV71
HPV102
95
100
(b)
Figure 1: Continued.4 The Scientiﬁc World Journal
H
P
V
8
4
HPV114
94
cHPV86
cHPV87
65
96
cHPV89
80
HPV83
55
HPV61
HPV72
85
HPV81
HPV62
98
75
96
HPV90
HPV106
100
63
HPV29
HPV3
HPV28
96
HPV117
HPV10
HPV94
98
99
99
HPV53
HPV30
96 HPV56
HPV66
99
93 HPV26
HPV69
89
HPV51
HPV82
98
89
HPV54
HPV45
HPV97 61
HPV18 90
cHPV85 56
HPV59
HPV39
HPV68
HPV70 87
73
76
HPV57
HPV27b
100
HPV13
PcPV1
99
HPV74
68
HPV44 HPV55
100
97
HPV6b HPV11
99
99
HPV43 HPV91
100
HPV7 HPV40
100
93
57
RhPV1
HPV34
HPV73
100
HPV32
HPV42
99
HPV52
HPV16
HPV31
HPV67
HPV33
HPV58
100
57
99
HPV1a
HPV63
94
H
P
V
4
HPV
6
5
96
HP
V95
10
0
HPV88
HPV116
HPV60
HPV50
HPV48
96
HPV112
HPV119
81
HPV103
HPV108
82
HPV101
96
HPV109
HPV123
99
HPV121
B52-FAB
99
72
58
HPV20
HPV21
58
HPV14D
79
HPV19 HPV25
93 99
HPV93 HPV24 HPV98
88 80
HPV124
HPV12
HPV99
HPV36
HPV8
HPV5
HPV47 64
85
79
HPV92
HPV96
67
HPV22
HPV120
HPV23
HPV100
79
HPV76
HPV75
93
HPV49
89
HPV115
HPV107
HPV104
91
HPV111
HPV113
76
HPV122
50
HPV9
HPV17
HPV37
72
HPV110
HPV38
HPV15
HPV80
99
50
52
98
55
58
58
HPV41
HPV2a
HPV71
HPV102
79
99
(c)
Figure 1: Phylogenetic analysis of L1 gene partial sequences ampliﬁed by (a) GP5+/GP6+, (b) CP primer set, and (c) FAB primer set in HPV
isolates. The trees were constructed by the UPGMA method using MEGA 4.0.2. The HPV isolates are marked with black triangles.
2.5. Statistical Data Processing. Data were processed by SPSS
statistical software program version 16.0. The correlations
were subjected to χ2 (Pearson chi-square) and Fisher’s exact
test. Odds ratios and logistic regression were also calculated.
Statistical signiﬁcance was set as a P-value less than 0.05.
3. Results
The characteristics of study subjects including age, HPV
DNA, HPV genotype, and breast cancer histopathologic
typesareshownin Table 1. Atotal of 130 individuals, includ-
ing79breastcancerpatientsand51noncancercontrols,were
recruited into this study (Table 1).
The mean ages were 47.77 ± 12.552 (S.D.) and 34.20 ±
9.704 (S.D.) years in breast cancer and control groups, re-
spectively (P ≤ 0.0001, Table 1). The most abundant type
of breast cancer determined histologically was IDC (84.8%),
followed by ILC (10.1%), MC (2.5%), DC, and IDL-ILC
(1.3%) (Table 1).
Statistical diﬀerence was observed in the HPV DNA
status (25.9% versus 2.4 0%, P = 0.002) and HPV genotype
(caser risk type, P = 0.005; tissue tropism type, P =
0.002) between these two groups (Table 1). HPV infection
has increased the risk of breast cancer and had an OR of
13.953 (95% CI 1.762–110.526; P = 0.002, Table 1).
The high-risk HPV types (HPV 16 and 18) were more
prevalent than other HPV types in the cases (14.0% versus
10.5%, Table 1). The HPV genotypes in samples of breast
cancer patients were 26.67% for HPV-16 (4 isolates) and
HPV-18(4isolates),13.3%forHPV-23(2isolates)andHPV-
6 (2 isolates), 6.67% for HPV-11 (1 isolate), HPV-15 (1 iso-
late), and HPV-124 (1 isolate), and one isolate could not be
genotyped compared to HPV reference sequences (Table 1)
while the sole detected HPV in control specimens was HPV-
124(Table 1).TheconstructedphylogenetictreesoftheHPV
isolates are shown in Figure 1 in 3 separate parts. The co-
infection with diﬀerent HPV types (HPV-16 and HPV-23)
was observed only in one sample, B32, which was detected
by GP and CP primer sets (Figures 1(a) and 1(b)).
In Table 2, HPV DNA detection rate is stratiﬁed by age
and breast cancer histopathologic types. No signiﬁcant dif-
ference was observed among breast tumor types considering
HPV status (Table 2). Due to incomparability of the age
means of case and control and to avoid the eﬀect of the age
parameter, a logistic regression model was run. Data shown
that age (OR 0.873, 95% CI 0.822–0.927; P ≤ 0.0001) and
HPV infection (OR 14.247, 95% CI 1.558–130.284; P =
0.019) are the signiﬁcant risk factors in breast carcinogenesis
in the studied women in north part of Iran, Mazandaran
province (Table 3).The Scientiﬁc World Journal 5
Table 1: The characteristics of study subjects and prevalence of HPV DNA status in breast cancer patients and noncancer controls.
Parameter Casesa (N = 79) Controlsa (N = 51) P-value
Age (year ± SD) 47.77 ±12.552 34.20 ±9.704 ≤0.0001 (t-test)
HPV 0.002
Positive 15 (25.9)b 1 (2.4) OR 13.953
Negative 43 (74.1) 40 (97.6) (95% CI 1.762–110.526)
HPV genotype (% within type)
HPV-124 1 (6.25) 1 (100)
HPV-23 2 (12.5)
HPV-18 4 (25)
HPV-16 4 (25)
HPV-15 1 (6.25)
HPV-11 1 (6.25)
HPV-6 2 (12.5)
Unknown 1 (6.25)
HPV genotype (% within subjects)
High-risk type 8 (14) 0 0.005
Low-risk type 6 (10.5) 1 (2.4)
Negative 43 (75.5) 40 (97.6)
HPV genotype (% within subjects)
Mucosal type 11 (19) 0 0.002
EV-cutaneous type 4 (6.9) 1 (2.4)
Negative 43 (74.1) 40 (97.6)
Tumor type (% within tumor type)
IDC 67 (84.8)
ILC 8 (10.1)
IDC-ILC mix 1 (1.3)
MC 2 (2.5)
DC 1 (1.3)
aSome of the subjects have been considered as missing value after quality examination of nucleic acid extraction.
bNumbers in parentheses are percentages.
Table 2: HPV status according to age groups and breast cancer histopathologic types.
Variable Cases Controls P-value
HPV positive (%) Number of subjects HPV positive (%) Number of subjects
Age (year)
<35 3 (49.9) 7 0 22 0.01
≥35 12 (23.5) 51 1 (7.7) 19 0.097
P-value 0.360 0.463
Tumor type
IDC 11 (22.9) 48
ILC 4 (66.7) 6
IDC-ILC 0 1
MC 0 2
DC 0 1
P-value 0.144
4. Discussion
HPVs belong to Papillomaviridae family, and epidemiolog-
ical studies have shown that a persistent HPV infection is
the most important risk factor for cervical cancer [28, 29].
HPVs are also considered to be one of the risk factors for
humanbreastcarcinogenesis.Theconceptoftherelationship
betweenHPVandbreastcancerisbasedontheidentiﬁcation
of HPV genome sequence in breast cancer tissues and
immortalization of primary mammary epithelial cells by
high-risk HPV [17–19]. However, involvement of HPV in
breast cancer is controversial. Since 1992, a growing number6 The Scientiﬁc World Journal
Table 3: The Breast cancer risk estimation using the logistic regres-
sion model according to HPV status and Age in Iran, Mazandaran
province.
Variable Number OR CI 95% P-value
Age 99 0.873 0.822–0.927 0.000
HPV 130 14.247 1.558–130.284 0.019
of studies had identiﬁed HPVs in breast tumors by PCR
around the world, with a positivity variation from 4% to
86% for suggesting negative [14–16, 30, 31]o rp o s i t i v er e l a -
tionships [6–13, 32–36]. These results reﬂect the controversy
in the role of HPV in the pathogenesis of breast cancer. The
controversy is inﬂuenced by the technical limitations and the
epidemiology of HPV in diﬀerent geographical area [36–38].
In our previous studies [20, 21], we showed that HPV
infection may be associated with the development of lung
cancer in Mazandaran, north part of Iran. It was worth men-
tioning that the HPV infection was the risk factor only in
male gender, not in females [20, 21] .I nt h i ss t u d y ,w eh a v e
evaluatedtheassociationbetweenthebreastcancerandHPV
infection in the north part of Iran. For the detection of HPV
DNA, FFPE tissues were analyzed by PCR using 3 diﬀerent
primer sets. As shown in Table 1, the detection frequency of
HPV DNA in breast cancer patients was signiﬁcantly higher
than that of control patients (25.9% versus 2.40%, P =
0.002). We suggest that HPV infection is signiﬁcantly related
to breast cancer in women live in Mazandaran province (OR
14.247, 95% CI 1.558–130.284; P = 0.019, Table 3). Regard-
ingtoHPVprevalenceinbreastcancer,ameta-analysisstudy
that explores the correlation between HPV infection and
risk of breast carcinoma revealed that HPV prevalence was
lowest in Europe (12.91%) and highest in Oceania (42.11%)
followed by Asia (32.42%) [38].
High-risk HPV types, such as HPV-16 and HPV-18, were
detected in our study, and they comprised the majority of
isolates (Table 1). Although there are great variability in the
HPV detection rate worldwide, the majority of HPV types
that are detected are the oncogenic types, HPV-16 and -18
[6–8, 11, 33, 38]. Our results are in agreement with these
previous reports (Table 1). In addition, we detected cuta-
neous HPV types (HPV-15, -23, and -124). The presence of
cutaneous HPV types was reported in the previous studies
among women with breast cancer or at increased risk for
breast cancer [10, 39]. The only isolate that screened by
the FAB primer set has no signiﬁcant similarity to any
known HPV types. Pairwise distance calculation revealed
that the HPV type 121 is the most similar type to the isolate
(Figure 1(c)) and the distance estimation is 0.235.
5. Conclusions
T h ep a t h o g e n e s i so fb r e a s tc a n c e ri sc o m p l e x .T h i ss t u d y
demonstrates the presence of HPV genome in tumor tissues
in women with breast cancer in north part of Iran. HPV
infection is associated with the development of breast cancer
in women live in Mazandaran province. Further studies are
needed to clarify the role and the risk assessment of HPV in
human breast cancer. Conﬁrming an etiologic role for HPV
in breast cancer in Iranian females may help develop vaccine
strategies for combating this increasingly common cancer.
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